Nitric oxide for inhalation in ST-elevation myocardial infarction (NOMI): a multicentre, double-blind, randomized controlled trial.

@article{Janssens2018NitricOF,
  title={Nitric oxide for inhalation in ST-elevation myocardial infarction (NOMI): a multicentre, double-blind, randomized controlled trial.},
  author={Stefan P. Janssens and Jan Bogaert and Jaroslaw Zalewski and Attila Toth and Tom Adriaenssens and Ann Belmans and Johan Bennett and Piet Claus and Walter J. Desmet and Christophe L. Dubois and Kaatje Goetschalckx and Peter R. Sinnaeve and Katleen Vandenberghe and Pieter Vermeersch and {\'A}rp{\'a}d Lux and Zsolt L{\'a}szl{\'o} Szelid and Monika Durak and Piotr Lech and Krzysztof Żmudka and Peter Pokreisz and Pascal Vranckx and B{\'e}la Merkely and Kenneth D. Bloch and Frans J J Van De Werf},
  journal={European heart journal},
  year={2018},
  volume={39 29},
  pages={
          2717-2725
        }
}
Aims Inhalation of nitric oxide (iNO) during myocardial ischaemia and after reperfusion confers cardioprotection in preclinical studies via enhanced cyclic guanosine monophosphate (cGMP) signalling. We tested whether iNO reduces reperfusion injury in patients with ST-elevation myocardial infarction (STEMI; NCT01398384). Methods and results We randomized in a double-blind, placebo-controlled study 250 STEMI patients to inhale oxygen with (iNO) or without (CON) 80 parts-per-million NO for 4 h… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 26 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-2 of 2 extracted citations

Similar Papers

Loading similar papers…